PLIAGLIS (lidocaine and tetracaine) by Crescita Therapeutics is amide-type local anesthetic agent and tetracaine is an ester-type local anesthetic agent. First approved in 2006.
Drug data last refreshed 14h ago · AI intelligence enriched 1w ago
PLIAGLIS is a topical cream combining lidocaine (amide-type) and tetracaine (ester-type) local anesthetics that block sodium ion channels to provide dermal analgesia. Applied to intact skin, it releases both agents to achieve localized pain relief. The product is indicated for topical dermatological anesthesia in procedural settings.
Product is in peak commercial phase with high competitive pressure (8/10), suggesting a mature, competitive market with established field and brand infrastructure.
amide-type local anesthetic agent and tetracaine is an ester-type local anesthetic agent. Both lidocaine and tetracaine block sodium ion channels required for the initiation and conduction of neuronal impulses which, in certain instances, results in local anesthesia. When applied to intact skin,…
Amide Local Anesthetic
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
A Non-interventional Study to Evaluate the Use of Pliaglis in Daily Practice
Evaluate Efficacy, Safety & Subject Satisfaction of Pain Management With Pliaglis® Cream for Dermal Filler Injections
Worked on PLIAGLIS at Crescita Therapeutics? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
LOE in ~5 years — strategic planning for patent cliff underway
Working on PLIAGLIS offers experience in a mature, competitive topical anesthetic market with established commercial infrastructure and high customer engagement. Roles focus on field execution, account management, and market defense against competitors rather than product launch or clinical development.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo